The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis
Open accessAbstract
BACKGROUND In early breast cancer (BC), there has been a trend to escalate endocrine therapy (ET) and to de-escalate chemotherapy (CT). However, the impact of ET versus CT on the quality of life (QoL) of early BC patients is unknown. Here, we characterize the independent contribution of ET and CT on patient-reported outcomes (PROs) at 2 years after diagnosis. PATIENTS AND METHODS We prospectively collected PROs in 4262 eligible patients using the European Organization for Research and Treatment of Cancer QLQ-C30/BR23 questionnaires inside CANTO trial (NCT01993498). The primary outcome was the C30 summary score (C30-SumSc) at 2 years after diagnosis. RESULTS From eligible patients, 37.2% were premenopausal and 62.8% postmenopausal; 81.9% received ET and 52.8% CT. In the overall cohort, QoL worsened by 2 years after diagnosis in multiple functions and symptoms; exceptions included emotional function and future perspective, which improved over time. ET (Pint = 0.004), but not CT (Pint = 0.924), had a persistent negative impact on the C30-SumSc. In addition, ET negatively impacted role and social function, pain, insomnia, systemic therapy side-effects, breast symptoms and further limited emotional function and future perspective recovery. Although CT had no impact on the C30-SumSc at 2-years it was associated with deteriorated physical and cognitive function, dyspnea, financial difficulties, body image and breast symptoms. We found a differential effect of treatment by menopausal status; in premenopausal patients, CT, despite only a non-significant trend for deteriorated C30-SumSc (Pint = 0.100), was more frequently associated with QoL domains deterioration than ET, whereas in postmenopausal patients, ET was more frequently associated with QoL deterioration, namely using the C30-SumSc (Pint = 0.004). CONCLUSION(S) QoL deterioration persisted at 2 years after diagnosis with different trajectories by treatment received. ET, but not CT, had a major detrimental impact on C30-SumSc, especially in postmenopausal women. These findings highlight the need to properly select patients for adjuvant ET escalation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer treatment and survivorship statistics, 2016
Miller, K. D., Siegel, R. L., Lin, C. C., Mariotto, A. B., Kramer, J. L., Rowland, J. H., Stein, K. D., Alteri, R., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21349 · Cited by 6,066
Cited by
Snijders, R., Brom, L., Theunissen, M., & van den Beuken-van Everdingen, M. (2023) · Cancers · doi:10.3390/cancers15030591 · Cited by 445
Piccart, M., van 't Veer, L. J., Poncet, C., Lopes Cardozo, J. M. N., Delaloge, S., Pierga, J.-Y., Vuylsteke, P., Brain, E., Vrijaldenhoven, S., Neijenhuis, P. A., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00007-3 · Cited by 369
Self-citationSystemic Therapy for Estrogen Receptor–Positive, HER2-Negative Breast Cancer
Burstein, H. J. (2020) · New England Journal of Medicine · doi:10.1056/nejmra1307118 · Cited by 316
Franzoi, M. A., Agostinetto, E., Perachino, M., Del Mastro, L., de Azambuja, E., Vaz-Luis, I., Partridge, A. H., & Lambertini, M. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30666-5 · Cited by 290
Self-citationDomingues, C., Santos, A., Alvarez-Lorenzo, C., Concheiro, A., Jarak, I., Veiga, F., Barbosa, I., Dourado, M., & Figueiras, A. (2022) · ACS Nano · doi:10.1021/acsnano.2c00128 · Cited by 235
Metadata
- Authors
- Ferreira, A. R., Di Meglio, A., Pistilli, B., Gbenou, A. S., El-Mouhebb, M., Dauchy, S., Charles, C., Joly, F., Everhard, S., Lambertini, M., Coutant, C., Cottu, P., Lerebours, F., Petit, T., Dalenc, F., Rouanet, P., Arnaud, A., Martin, A., Berille, J., Ganz, P. A., Partridge, A. H., Delaloge, S., Michiels, S., Andre, F., & Vaz-Luis, I.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2019-11
- Volume
- 30
- Issue
- 11
- Pages
- 1784-1795
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2980243529
- Cited by
- 230
- References
- 1
- FWCI
- 8.98
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis. https://app.cochat.ai/papers/10.1093/annonc/mdz298
- The paper
- Ferreira, A. R., Di Meglio, A., Pistilli, B., Gbenou, A. S., El-Mouhebb, M., Dauchy, S., Charles, C., Joly, F., Everhard, S., Lambertini, M., Coutant, C., Cottu, P., Lerebours, F., Petit, T., Dalenc, F., Rouanet, P., Arnaud, A., Martin, A., Berille, J., . . . Vaz-Luis, I. (2019). Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis. Annals of Oncology. https://doi.org/10.1093/annonc/mdz298
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.